Grace Therapeutics Files 8-K on Agreements and Equity Sales

Ticker: GRCE · Form: 8-K · Filed: Feb 10, 2025 · CIK: 1444192

Grace Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyGrace Therapeutics, INC. (GRCE)
Form Type8-K
Filed DateFeb 10, 2025
Risk Levelmedium
Pages6
Reading Time7 min
Key Dollar Amounts$0.0001, $3.395, $3.3949, $0.125, $13.8 m
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, equity-sale, corporate-action

TL;DR

Grace Therapeutics (formerly Acasti Pharma) filed an 8-K detailing new deals and stock sales.

AI Summary

Grace Therapeutics, Inc. filed an 8-K on February 10, 2025, reporting on a material definitive agreement, unregistered sales of equity securities, and other events. The company, formerly known as Acasti Pharma Inc. until August 28, 2008, is incorporated in Delaware and headquartered in Princeton, New Jersey.

Why It Matters

This filing provides updates on significant corporate actions, including material agreements and equity transactions, which can impact the company's financial standing and future operations.

Risk Assessment

Risk Level: medium — The filing mentions unregistered sales of equity securities, which can sometimes indicate dilution or financial distress.

Key Numbers

Key Players & Entities

FAQ

What specific material definitive agreement was entered into by Grace Therapeutics?

The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the excerpt.

What was the nature of the unregistered sales of equity securities?

The filing notes unregistered sales of equity securities, but the excerpt does not specify the terms, volume, or recipients of these sales.

What are the 'Other Events' reported in this 8-K?

The filing lists 'Other Events' as a category, but the specific events are not detailed in the provided text.

When did Grace Therapeutics change its name from Acasti Pharma Inc.?

Grace Therapeutics, Inc. was formerly known as Acasti Pharma Inc. until August 28, 2008.

Where are Grace Therapeutics' principal executive offices located?

Grace Therapeutics, Inc.'s principal executive offices are located at 103 Carnegie Center, Suite 300, Princeton, New Jersey 08540.

Filing Stats: 1,773 words · 7 min read · ~6 pages · Grade level 11.3 · Accepted 2025-02-10 08:11:31

Key Financial Figures

Filing Documents

02

Item 3.02. Unregistered Sales of Equity Securities. The disclosures in Item 1.01 of this Current Report on Form 8-K regarding the Offering are incorporated by reference into this Item 3.02.

01

Item 8.01. Other Events. On February 10, 2025, the Company issued a press release announcing the top line results of the pivotal Phase 3 STRIVE-ON safety trial. The Phase 3 STRIVE-ON Safety trial met its primary endpoint and provided evidence of clinical benefit over orally administered nimodipine. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 8.01. On February 10, 2025, the Company posted an updated investor presentation on its website. A copy of the presentation is attached hereto as Exhibit 99.2 and is incorporated by reference into this Item 8.01. On February 10, 2025, the Company issued a press release announcing the Offering. A copy of the press release is attached hereto as Exhibit 99.3 and is incorporated by reference into this Item 8.01 .

01

Item 9.01. Exhibits. (d) Exhibits Exhibit Description 4.1 Form of Pre-Funded Warrant. 4.2 Form of Common Warrant. 10.1 Form of Placement Agent Securities Purchase Agreement . 10.2 Form of Non-Placement Agent Securities Purchase Agreement . 10.3 Form of Registration Rights Agreement. 99.1 Press Release, dated February 10, 2025. 99.2 Investor Presentation, dated February 10, 2025. 99.3 Press Release, dated February 10, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. GRACE THERAPEUTICS, INC. Date: February 10 , 2025 By: /s/ Prashant Kohli Prashant Kohli Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing